Nektar Therapeutics has been granted a patent for a long-acting interleukin-15 (IL-15) receptor agonist. The composition includes poly(ethylene glycol)-interleukin-15 moiety conjugates, aimed at enhancing immune activation and anti-tumor activity in therapeutic applications. GlobalData’s report on Nektar Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Nektar Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Nektar Therapeutics's grant share as of June 2024 was 55%. Grant share is based on the ratio of number of grants to total number of patents.
Long-acting il-15 receptor agonist for immune activation
The granted patent US12036283B2 outlines a long-acting interleukin-15 (IL-15) receptor agonist composition, primarily consisting of poly(ethylene glycol)-interleukin-15 moiety conjugates. The claims specify various formulations of these conjugates, including limitations on the mole percent of specific IL-15 conjugates and the average number of polyethylene glycol moieties attached to IL-15. The composition is designed to maintain a reduced effective concentration (EC50) and receptor alpha binding affinity (KD) compared to unmodified IL-15, ensuring that the therapeutic efficacy is preserved while enhancing the longevity of the IL-15 activity in the body.
Additionally, the patent details the structural characteristics of the IL-15 moieties, including their sequence identity to a reference sequence (SEQ ID NO:1) and the potential for deamidation. The composition is intended for parenteral administration and may include various pharmaceutically acceptable excipients such as buffers, carbohydrates, and surfactants to enhance stability and solubility. The formulation is specified to be in an aqueous medium with a pH range of approximately 6.5 to 7.0, optimizing conditions for therapeutic use. Overall, the patent presents a comprehensive approach to improving the pharmacokinetics of IL-15 through innovative conjugation techniques.
To know more about GlobalData’s detailed insights on Nektar Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
